Clinical features of patients at diagnosis
| Parameters . | Total . | Maintenance chemotherapy . | Observation . | P* . | |||
|---|---|---|---|---|---|---|---|
| No. (%) . | Median (range) . | No. (%) . | Median (range) . | No. (%) . | Median (range) . | ||
| No. of patients | 283 | 89 | 86 | ||||
| Sex | |||||||
| Male | 158 (56) | 53 (60) | 47 (55) | .51 | |||
| Female | 125 (44) | 36 (40) | 39 (45) | ||||
| Age, years | 48 (15-70) | 49 (15-70) | 46 (16-67) | .70 | |||
| 15-29 | 49 (17) | 17 (19) | 15 (17) | ||||
| 30-49 | 106 (37) | 32 (36) | 34 (40) | .88 | |||
| 50-70 | 128 (45) | 40 (45) | 37 (43) | ||||
| FAB Morphology | |||||||
| M3 | 265 (93) | 80 (90) | 82 (95) | .25 | |||
| M3v | 18 (6) | 9 (10) | 4 (5) | ||||
| Leukocyte count, ×109/L | 1.7 (0.03-257) | 1.9 (0.03-152) | 2.1 (0.1-98) | .95 | |||
| Less than 3.0 | 174 (61) | 50 (56) | 47 (55) | ||||
| 3.0-10.0 | 58 (20) | 21 (24) | 20 (23) | .95 | |||
| 10.0 or higher | 51 (18) | 18 (20) | 19 (22) | ||||
| Platelet count, ×109/L | 30 (2-238) | 31 (4-230) | 23 (2-238) | .10 | |||
| Less than 10 | 39 (14) | 8 (9) | 16 (19) | ||||
| 10-40 | 140 (49) | 47 (53) | 41 (48) | .18 | |||
| 40 or higher | 104 (37) | 34 (38) | 29 (34) | ||||
| Induction therapy# | |||||||
| Group A | 85 (30) | 29 (33) | 29 (34) | 1.0 | |||
| Group AD | 66 (23) | 17 (19) | 16 (19) | ||||
| Group B+BD | 73 (26) | 23 (26) | 22 (26) | ||||
| Group C | 52 (18) | 20 (22) | 19 (22) | ||||
| Unknown | 7 (2) | NA | NA | ||||
| Parameters . | Total . | Maintenance chemotherapy . | Observation . | P* . | |||
|---|---|---|---|---|---|---|---|
| No. (%) . | Median (range) . | No. (%) . | Median (range) . | No. (%) . | Median (range) . | ||
| No. of patients | 283 | 89 | 86 | ||||
| Sex | |||||||
| Male | 158 (56) | 53 (60) | 47 (55) | .51 | |||
| Female | 125 (44) | 36 (40) | 39 (45) | ||||
| Age, years | 48 (15-70) | 49 (15-70) | 46 (16-67) | .70 | |||
| 15-29 | 49 (17) | 17 (19) | 15 (17) | ||||
| 30-49 | 106 (37) | 32 (36) | 34 (40) | .88 | |||
| 50-70 | 128 (45) | 40 (45) | 37 (43) | ||||
| FAB Morphology | |||||||
| M3 | 265 (93) | 80 (90) | 82 (95) | .25 | |||
| M3v | 18 (6) | 9 (10) | 4 (5) | ||||
| Leukocyte count, ×109/L | 1.7 (0.03-257) | 1.9 (0.03-152) | 2.1 (0.1-98) | .95 | |||
| Less than 3.0 | 174 (61) | 50 (56) | 47 (55) | ||||
| 3.0-10.0 | 58 (20) | 21 (24) | 20 (23) | .95 | |||
| 10.0 or higher | 51 (18) | 18 (20) | 19 (22) | ||||
| Platelet count, ×109/L | 30 (2-238) | 31 (4-230) | 23 (2-238) | .10 | |||
| Less than 10 | 39 (14) | 8 (9) | 16 (19) | ||||
| 10-40 | 140 (49) | 47 (53) | 41 (48) | .18 | |||
| 40 or higher | 104 (37) | 34 (38) | 29 (34) | ||||
| Induction therapy# | |||||||
| Group A | 85 (30) | 29 (33) | 29 (34) | 1.0 | |||
| Group AD | 66 (23) | 17 (19) | 16 (19) | ||||
| Group B+BD | 73 (26) | 23 (26) | 22 (26) | ||||
| Group C | 52 (18) | 20 (22) | 19 (22) | ||||
| Unknown | 7 (2) | NA | NA | ||||
Baseline characteristics of the two randomized groups were compared with Chi-squqre test or Wilcoxon rank-sum test.
Patients in Group A were treated with ATRA alone; patients in Groups B and C were treated with ATRA plus idarubicin and cytarabine. Patients in Groups A and B who received an additional cycle of chemotherapy due to increased leukemic cells during induction were designated as Groups AD and BD, respectively. Four patients were in Group BD.
NA indicates not applicable.